Patents by Inventor Tomohiro Nishizawa
Tomohiro Nishizawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170173112Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine ROTHE, Andreas HOHLBAUM, Andrea ALLERSDORFER, Rachida Siham Bel AIBA, Marlon HINNER, Alexander WIEDENMANN, Bradley LUNDE, Shinji YAMAGUCHI, Takahide ABURATANI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Chikako NAGASAKI, Futoshi NARA, Tomohiro NISHIZAWA
-
Patent number: 9598476Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: August 28, 2015Date of Patent: March 21, 2017Assignee: Daiichi Sankyo Co., Ltd.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20160024161Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: August 28, 2015Publication date: January 28, 2016Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9150563Abstract: The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.Type: GrantFiled: February 10, 2014Date of Patent: October 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Keiko Suzuki, Takahiro Yamaguchi, Akihiro Tamura, Tomohiro Nishizawa, Mitsuhiro Yamaguchi
-
Patent number: 9150629Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: March 13, 2014Date of Patent: October 6, 2015Assignee: DAIICHI SANKYO CO., LTD.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140187592Abstract: The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Keiko Suzuki, Takahiro Yamaguchi, Akihiro Tamura, Tomohiro Nishizawa, Mitsuhiro Yamaguchi
-
Patent number: 8648103Abstract: The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH; each R2 represents an alkyl; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.Type: GrantFiled: July 7, 2009Date of Patent: February 11, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Keiko Suzuki, Takahiro Yamaguchi, Akihiro Tamura, Tomohiro Nishizawa, Mitsuhiro Yamaguchi
-
Publication number: 20120108639Abstract: The present invention provides a compound having excellent regulating action on blood lipid level that is represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein, in one embodiment, A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH; each R2 represents an alkyl; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.Type: ApplicationFiled: July 7, 2009Publication date: May 3, 2012Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Keiko Suzuki, Takahiro Yamaguchi, Akihiro Tamura, Tomohiro Nishizawa, Mitsuhiro Yamaguchi